Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ARRY-382 is an inhibitor of the colony-stimulating factor 1 receptor (CSF1R; IC50 = 9 nM).1 It is selective for CSF1R over PDGFR, c-Kit, and FMS-related tyrosine kinase 3 (FLT3; IC50s = >10,000 nM for all). ARRY-382 (10 µM) induces apoptosis in several primary human chronic lymphocytic leukemia (CLL) cell lines. It also enhances the cytotoxicity of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Item No. 16274) and PI3K p110δ inhibitor idelalisib (CAL-101; Item No. 15279) in several primary human CLL cell lines when used at concentrations ranging from 0.15625 to 10 µM.
WARNING This product is not for human or veterinary use.
1. Targeting of colony-